Loading...
XSTO
MVIR
, Last price  
SEK
Name

Medivir AB

Chart & performance

D1W1MN
XSTO:MVIR chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
31.64%
Rev. 5Y
-9.43%
Div Yld LY
—
Div Yld TTM
—
Revenues
9m
+143.90%
129,335,000253,463,000101,975,00035,498,00057,288,000698,566,000170,647,000446,146,0001,766,989,000474,274,00093,043,00036,639,00023,863,0008,724,00013,948,00025,538,0004,408,0007,634,0003,485,0008,500,000
Net income
-94m
L-23.45%
-195,580,000-29,318,000-99,203,000-135,375,000-134,227,000113,751,000-234,098,00016,014,0001,132,735,00031,708,000-294,856,000-360,218,000-350,314,000-123,440,000-42,620,000-63,125,000-88,765,000-89,322,000-123,317,000-94,400,000
CFO
-73m
L-40.90%
-90,532,000-75,499,000-34,851,000-135,086,000-76,871,00057,262,000-139,564,00043,041,0001,014,363,000347,387,000-182,284,000-358,480,000-318,630,000-148,255,000-58,053,000-48,734,000-101,820,000-59,665,000-124,191,000-73,400,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Established in 1987 and headquartered in Huddinge, Sweden, Medivir AB (publ) is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products. Its primary therapeutic area is oncology, with operations extending across Sweden and internationally. The company's marketed product, Zoviduo (also known as Xerclear), treats labial herpes. Medivir's robust pipeline features several investigational compounds: Remetinostat for MF cutaneous T-cell lymphoma and basal cell carcinoma; MIV-818 for liver cancer; MIV-711 for osteoarthritis; and Birinapant along with IGM-8444, both targeting solid tumors. Furthermore, Medivir engages in strategic collaborations, including a research partnership with SciLifeLab's Drug Discovery and Development Platform to discover antivirals for SARS-CoV-2, and has licensing agreements with Tango Therapeutics and Ubiquigent Limited for preclinical research programs, specifically Ubiquigent's USP7 program.

Key people

Magnus Christensen
Chief Financial Officer · since 2019
Fredrik Oberg
Chief Scientific Officer · since 2019
Lennart Hansson
Director · since 2018
Bjorn Klasson
Director, Employee Representative · since 2017
Uli Hacksell
President, Chief Executive Officer, Independent Director · since 2018
Bengt Julander
Independent Director · since 2017
Helena Levander
Independent Chairman of the Board · since 2019
Bengt Westermark
Independent Director · since 2017
URL
https://www.medivir.se/
IPO date
Feb 29, 1996
Employees
10
Domiciled in
SE
Incorporated in
SE
Headquarters & legal address
Lunastigen 5
Huddinge, AB 141 44
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT